- Home
- RDHL vs CDT Comparison
RDHL vs CDT Comparison
Compare RDHL & CDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDHL
- CDT
- Stock Information
- Founded
- RDHL 2009
- CDT 2019
- Country
- RDHL Israel
- CDT United States
- Employees
- RDHL N/A
- CDT N/A
- Industry
- RDHL Biotechnology: Pharmaceutical Preparations
- CDT Biotechnology: Pharmaceutical Preparations
- Sector
- RDHL Health Care
- CDT Health Care
- Exchange
- RDHL Nasdaq
- CDT Nasdaq
- Market Cap
- RDHL 3.9M
- CDT 4.6M
- IPO Year
- RDHL N/A
- CDT N/A
- Fundamental
- Price
- RDHL $1.70
- CDT $0.90
- Analyst Decision
- RDHL
- CDT
- Analyst Count
- RDHL 0
- CDT 0
- Target Price
- RDHL N/A
- CDT N/A
- AVG Volume (30 Days)
- RDHL 43.1K
- CDT 12.0M
- Earning Date
- RDHL 09-05-2025
- CDT 11-13-2025
- Dividend Yield
- RDHL N/A
- CDT N/A
- EPS Growth
- RDHL N/A
- CDT N/A
- EPS
- RDHL N/A
- CDT N/A
- Revenue
- RDHL $9,550,000.00
- CDT N/A
- Revenue This Year
- RDHL $381.91
- CDT N/A
- Revenue Next Year
- RDHL N/A
- CDT N/A
- P/E Ratio
- RDHL N/A
- CDT N/A
- Revenue Growth
- RDHL 157.62
- CDT N/A
- 52 Week Low
- RDHL $1.06
- CDT $0.57
- 52 Week High
- RDHL $11.70
- CDT $274.80
- Technical
- Relative Strength Index (RSI)
- RDHL 63.39
- CDT 36.45
- Support Level
- RDHL $1.47
- CDT $0.57
- Resistance Level
- RDHL $1.60
- CDT $0.68
- Average True Range (ATR)
- RDHL 0.09
- CDT 0.10
- MACD
- RDHL 0.04
- CDT -0.01
- Stochastic Oscillator
- RDHL 97.98
- CDT 36.62
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.
About CDT Conduit Pharmaceuticals Inc.
CDT Equity Inc, formerly Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being prioritized by biopharmaceutical companies to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready for autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor, and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.